1. Home
  2. AGIO vs QS Comparison

AGIO vs QS Comparison

Compare AGIO & QS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • QS
  • Stock Information
  • Founded
  • AGIO 2007
  • QS 2010
  • Country
  • AGIO United States
  • QS United States
  • Employees
  • AGIO N/A
  • QS N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • QS Auto Parts:O.E.M.
  • Sector
  • AGIO Health Care
  • QS Consumer Discretionary
  • Exchange
  • AGIO Nasdaq
  • QS Nasdaq
  • Market Cap
  • AGIO 3.0B
  • QS 2.7B
  • IPO Year
  • AGIO 2013
  • QS N/A
  • Fundamental
  • Price
  • AGIO $55.54
  • QS $5.04
  • Analyst Decision
  • AGIO Buy
  • QS Hold
  • Analyst Count
  • AGIO 7
  • QS 5
  • Target Price
  • AGIO $52.33
  • QS $6.26
  • AVG Volume (30 Days)
  • AGIO 737.4K
  • QS 11.6M
  • Earning Date
  • AGIO 10-31-2024
  • QS 10-23-2024
  • Dividend Yield
  • AGIO N/A
  • QS N/A
  • EPS Growth
  • AGIO N/A
  • QS N/A
  • EPS
  • AGIO 11.80
  • QS N/A
  • Revenue
  • AGIO $32,871,000.00
  • QS N/A
  • Revenue This Year
  • AGIO $33.38
  • QS N/A
  • Revenue Next Year
  • AGIO $163.06
  • QS N/A
  • P/E Ratio
  • AGIO $4.70
  • QS N/A
  • Revenue Growth
  • AGIO 36.79
  • QS N/A
  • 52 Week Low
  • AGIO $20.96
  • QS $4.65
  • 52 Week High
  • AGIO $62.58
  • QS $10.03
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 62.15
  • QS 46.33
  • Support Level
  • AGIO $52.09
  • QS $4.65
  • Resistance Level
  • AGIO $62.58
  • QS $5.17
  • Average True Range (ATR)
  • AGIO 2.85
  • QS 0.22
  • MACD
  • AGIO -0.06
  • QS 0.01
  • Stochastic Oscillator
  • AGIO 63.58
  • QS 63.11

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

About QS QuantumScape Corporation

QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed an anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.

Share on Social Networks: